C4 Therapeutics, Inc.

NASDAQ:CCCC

Biotechnology

Healthcare
$2.48 +2.06%

+$0.08 today

Market cap
$325.01M
Beta
2.93
P/E (TTM)
-4.9
EPS (TTM)
-$0.82
52W Low $1.36High $4.60

Volume 2.75M

Average 2.76M

CCCC Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

C4 Therapeutics, Inc.NASDAQ: CCCC

Accounts Payables · Q1 FY2026 · quarter ended Mar 2026

Accounts payables dips below year-ago levels

Q1 FY2026 accounts payables of $85K (cash outflow) fell 86.8% year over year, behind the +109.7% change in trailing-twelve-month accounts payables. Sequentially, it fell 82.0% from the prior quarter. Over 3 fiscal years it compounded at -48.0% a year.

Context

  • Accounts payables amounted to 1.3% of revenue in FY2025, up 1.0 pp from a year earlier.
  • Accounts payables increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -86.8% toward the trailing-twelve-month pace of +109.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$85K-82.0% QoQ
Last fiscal yearDec 2025
-$468K+293.3% YoY
LTMMar 2026
$92K+109.7% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-86.8%——
1 year+293.3%——
3-year CAGR-48.0%——
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
(468K) USD
Year-over-year change
-293.3%

Accounts Payables vs competitors

How CCCC compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +109.7% is the 3rd highest of 9, against a peer median of -51.5%.
  • Accounts payables amounts to 0.3% of revenue for CCCC, versus a peer median of 7.3%.
CCCC Competitors
Accounts Payables for CCCC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$7.58M USD+55.9%—425.1%
SGMOSangamo Therapeutics, Inc.LTM Mar 2026$3.51M USD+170.1%-40.6%10.2%
CDXSCodexis, Inc.LTM Mar 2026$3.04M USD-297.9%—3.9%
PEPGPepGen Inc.LTM Mar 2026$2.06M USD-230.7%-12.7%—
MOLNMolecular Partners AGLTM Mar 2026CHF 504.13K CHF-32.5%——
IMDXInsight Molecular Diagnostics Inc.LTM Mar 2026$337K USD-70.4%+107.3%17.3%
OABIOmniAb, Inc.LTM Mar 2026$215K USD+111.0%—0.7%
ARMPArmata Pharmaceuticals, Inc.LTM Mar 2026$133K USD-95.3%—4.5%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$92K USD+109.7%-48.0%0.3%
Peer median (excluding CCCC) —-51.5%-12.7%7.3%

Competitors are the stored peer set for CCCC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(83.89M)(128.18M)(132.49M)(105.32M)(104.99M)
Depreciation & Amortization1.49M1.68M1.88M1.82M1.96M
Deferred Income Tax1.88M0000
Stock-Based Compensation21.51M30.02M27.24M29.66M19.1M
Change in Working Capital(30.09M)(16.78M)(6.94M)7.65M(29.28M)
Accounts Receivables(1.23M)4.24M(10.33M)8.7M701K
Inventory(2.63M)0000
Accounts Payables(1.18M)(3.33M)273K(119K)(468K)
Other Working Capital(25.05M)(17.69M)3.12M(930K)(29.52M)
Other Non-Cash Items2.13M7.32M3.48M1.03M14.52M
Operating Cash Flow(86.97M)(105.94M)(106.84M)(65.16M)(98.69M)
Capital Expenditures(1.28M)(5.5M)(1.71M)(180K)(607K)
Acquisitions (Net)188.06M(63.92M)000
Purchases of Investments(537.74M)(219.53M)(129.9M)(284.32M)(227.07M)
Sales of Investments349.68M283.45M289.96M233.23M219.08M
Other Investing Activities(188.06M)63.92M000
Investing Cash Flow(189.34M)58.42M158.35M(51.27M)(8.6M)
Debt Repayment00(12.5M)00
Common Stock Issued169.47M777K57.67M44.37M126.32M
Common Stock Repurchased00(110K)(194K)(193K)
Dividends Paid00000
Other Financing Activities1.94M370K426K1.16M274K
Financing Cash Flow171.4M1.15M45.49M45.34M126.4M
Effect of Forex Changes00000
Net Change in Cash(104.9M)(46.37M)97M(71.09M)19.1M
Free Cash Flow(88.24M)(111.44M)(108.55M)(65.34M)(99.3M)

C4 Therapeutics, Inc.

NASDAQ:CCCC

Intrinsic Alpha fair value

Locked

Current Price

$2.48

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.